We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
-1.19%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.78B
AUM Growth
-$1.32B
(-15%)
Cap. Flow
-$329M
Cap. Flow
% of AUM
-4.22%
Top 10 Holdings %
Top 10 Hldgs %
29.03%
Holding
186
New
13
Increased
33
Reduced
45
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$254M |
| 2 |
Pfizer
PFE
|
+$130M |
| 3 |
Compass Therapeutics
CMPX
|
+$71.8M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$64.9M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$61.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$156M |
| 2 |
Elevance Health
ELV
|
+$77.2M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$74.2M |
| 4 |
Progyny
PGNY
|
+$71.1M |
| 5 |
CRISPR Therapeutics
CRSP
|
+$68.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.32% |
| 2 | Industrials | 0% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Spyre Therapeutics
SYRE
$8.68B
| $14M | 0.18% |
118,245
-42,376
| -26% | -$6.69M |
|
102
Pulmonx
LUNG
$52.8M
| $13.9M | 0.18% |
435,000
| – | – |
|
103
CytomX Therapeutics
CTMX
$701M
| $13.9M | 0.18% |
3,214,509
+1,392,641
| +76% | +$8.16M |
|
|
BNR
104
Burning Rock Biotech
BNR
$96.9M
| $13.8M | 0.18% |
145,240
-40,380
| -22% | -$5.53M |
|
|
FUSN
105
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $13.4M | 0.17% |
3,224,770
| – | – |
|
106
Amgen
AMGN
$212B
| $12.8M | 0.17% |
57,100
| – | – |
|
|
HELP
107
Cybin Inc
HELP
$471M
| $12.5M | 0.16% |
276,955
-76,917
| -22% | -$4.87M |
|
108
Cullinan Oncology
CGEM
$1.07B
| $12.4M | 0.16% |
805,041
-341,104
| -30% | -$6.8M |
|
|
DMRA
109
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.81B
| $12.4M | 0.16% |
163,637
| – | – |
|
110
uniQure
QURE
$2.52B
| $12.1M | 0.16% |
585,574
| – | – |
|
|
BLU
111
DELISTED
BELLUS Health Inc.
BLU
| $11.7M | 0.15% |
1,454,800
-1,000,000
| -41% | -$6.64M |
|
|
SONX
112
DELISTED
Sonendo, Inc.
SONX
| $11.3M | 0.15% |
+1,968,180
| New | +$17.7M |
|
|
NMTR
113
DELISTED
9 Meters Biopharma
NMTR
| $10.1M | 0.13% |
513,794
+85,495
| +20% | +$1.91M |
|
114
Dianthus Therapeutics
DNTH
$5.55B
| $9.97M | 0.13% |
140,685
+22,375
| +19% | +$2.25M |
|
|
RXDX
115
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $9.88M | 0.13% |
250,000
| – | – |
|
116
Enliven Therapeutics
ELVN
$3.84B
| $9.87M | 0.13% |
1,096,642
| – | – |
|
117
Vor Biopharma
VOR
$1.08B
| $9.68M | 0.12% |
41,667
| – | – |
|
|
AFIB
118
DELISTED
Acutus Medical Inc
AFIB
| $9.03M | 0.12% |
2,648,386
| – | – |
|
119
CVRx
CVRX
$131M
| $8.84M | 0.11% |
723,055
-76,806
| -10% | -$1.11M |
|
|
RAPT
120
DELISTED
RAPT Therapeutics
RAPT
| $7.97M | 0.1% |
+27,125
| New | +$7.25M |
|
|
ACHL
121
DELISTED
Achilles Therapeutics
ACHL
| $7.94M | 0.1% |
1,584,845
| – | – |
|
122
Gossamer Bio
GOSS
$100M
| $7.72M | 0.1% |
+683,000
| New | +$8.11M |
|
123
CalciMedica
CALC
$11.3M
| $7.62M | 0.1% |
297,382
| – | – |
|
|
IMDX
124
Insight Molecular Diagnostics
IMDX
$149M
| $7.58M | 0.1% |
174,690
+31,890
| +22% | +$1.83M |
|
125
Nautilus Biotechnolgy
NAUT
$152M
| $7.53M | 0.1% |
1,452,774
| – | – |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q4 2021 Portfolio in Review
As of Q4 2021, OrbiMed held 186 positions worth $7.78B, down 15% from $9.1B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
OrbiMed withdrew a net $329M in Q4 2021, closing 29 positions and reducing 45 holdings. Its most notable exit was Elevance Health, an estimated $77.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Industrials and Technology.
Against the trend, OrbiMed opened a new position in Theseus Pharmaceuticals, Inc. Common Stock worth $214M.
- OrbiMed's largest Q4 2021 buy was Theseus Pharmaceuticals, Inc. Common Stock: 16,838,668 shares worth $214M.
- OrbiMed added most to Seagen Inc. Common Stock in Q4 2021, an estimated $64.9M increase.
- OrbiMed's biggest Q4 2021 reduction was Merck, cutting an estimated $156M.
- OrbiMed fully exited Elevance Health in Q4 2021, selling an estimated $77.2M.
- OrbiMed's ten largest holdings make up 29% of its $7.78B portfolio in Q4 2021.
- OrbiMed opened 13 new positions and closed 29 in Q4 2021.
- OrbiMed's portfolio value fell 15% quarter-over-quarter to $7.78B.
Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.